Skip to main content
SpringerLink
Log in

Apremilast prescriptions expected to double in next month

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. disease-modifying antirheumatic drug

Reference

  • Decision Resources. Surveyed U.S. Rheumatologists' Experience Prescribing Celgene's Otezla at One Month Post Launch Is Less Than 30 Percent But Is Expected to More Than Double Within the Next Month. Media Release : 4 Aug 2014. Available from: URL: http://www.decisionresourcesgroup.com

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apremilast prescriptions expected to double in next month. PharmacoEcon Outcomes News 709, 10 (2014). https://doi.org/10.1007/s40274-014-1468-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1468-9

Search

Navigation